NCT03299335 (IBM-RNAseq) is a NA clinical trial of Blood collection in Inclusion Body Myositis, sponsored by Centre Hospitalier Universitaire de Nice.

Who is sponsoring NCT03299335?

NCT03299335 is sponsored by Centre Hospitalier Universitaire de Nice.

What drugs are being tested in NCT03299335?

Interventions in NCT03299335: Blood collection.

What condition does NCT03299335 study?

NCT03299335 studies Inclusion Body Myositis.

Is NCT03299335 still recruiting?

NCT03299335 is currently completed. Last updated 22 March 2023.

Last reviewed 2023-03-22 · How we verify

NCT03299335: IBM-RNAseq

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molecular Profile of the Evolution of Inclusion Body Myositis

Completed NA Last updated 22 March 2023

What this trial tests

NA trial testing Blood collection in Inclusion Body Myositis in 4 participants. Completed in 7 February 2020.

Timeline

1 February 2018

Primary endpoint
7 February 2019

7 February 2020

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nice
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	4
Start date	1 February 2018
Primary completion	7 February 2019
Estimated completion	7 February 2020
Sites	1 location across France

Drugs / interventions tested

Blood collection — full drug profile →

Conditions studied

Inclusion Body Myositis — all drugs for Inclusion Body Myositis →

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

18 and older, any sex, with Inclusion Body Myositis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of control subject. The investigators use the RNA-seq technique to analyze the gene expression levels and potential alternate transcripts, including long non-coding RNAs (lncRNAs), in muscle tissue samples. The gene expression profiles will point to the genes of interest that can then become the object of future studies, in which epigenetic changes of these genes will be explored further. The value of those possible biomarkers will be assessed. The investigators will also evaluate the correlation between the gene expression profile, the degree of functional impairment, the histological picture and the presence or absence of autoantibodies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Long non-coding RNAs in the failing heart and vasculature.
Hermans-Beijnsberger S, van Bilsen M, Schroen B. · · 2018 · cited 43× · PMID 30175285 · DOI 10.1016/j.ncrna.2018.04.002

Verify or expand the search:

Other trials of Blood collection

Trials testing the same drug.

NCT07134491 — Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, · recruiting
NCT07075107 — Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases · NA · not yet recruiting
NCT06510868 — Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy · recruiting
NCT06521502 — The APS Phenotyping Study · recruiting
NCT06373510 — Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration · NA · not yet recruiting

Other recruiting trials for Inclusion Body Myositis

Currently open trials in the same condition.

NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT05046821 — Sporadic Inclusion Body Myositis Natural History Study · active not recruiting
NCT00017914 — Adult and Juvenile Myositis · recruiting

Other Centre Hospitalier Universitaire de Nice trials

Trials by the same sponsor.

NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03299335 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
Last refreshed: 22 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03299335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing